

Erratum

## Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. *Brain Sci.* 2020, 10, 176

Javier Pagonabarraga <sup>1,2,3,\*</sup>, José Matías Arbelo <sup>4,5</sup>, Francisco Grandas <sup>6,7</sup>,  
Maria-Rosario Luquin <sup>8,9</sup>, Pablo Martínez Martín <sup>10,11</sup>, Maria Cruz Rodriguez-Oroz <sup>12,13</sup>,  
Francesc Valldeoriola <sup>14,15</sup> and Jaime Kulisevsky <sup>1,2,3,16,17</sup>

- <sup>1</sup> Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain; jkulisevsky@santpau.cat
- <sup>2</sup> Department of Medicine, Autonomous University of Barcelona, 08193 Barcelona, Spain
- <sup>3</sup> Centro de Investigación en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
- <sup>4</sup> Movement Disorders Unit, Neurology Department, Hospital Universitario San Roque, 35001 Las Palmas, Spain; jmarbelo@gmail.com
- <sup>5</sup> Department of Medicine, Universidad Fernando Pessoa-Canarias, 35450 Las Palmas, Spain
- <sup>6</sup> Movement Disorders Unit-CSUR, Neurology Department, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain; francisco.grandas@salud.madrid.org
- <sup>7</sup> Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
- <sup>8</sup> Movement Disorders Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain; rluquin@unav.es
- <sup>9</sup> Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
- <sup>10</sup> Instituto de Salud Carlos III, 28029 Madrid, Spain; pmm650@hotmail.com
- <sup>11</sup> Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
- <sup>12</sup> Neurology and Neuroscience Unit, Clínica Universidad de Navarra (CUN), 31008 Pamplona, Spain; mcroroz@unav.es
- <sup>13</sup> Centre for Applied Medical Research (CIMA), 31008 Pamplona, Spain
- <sup>14</sup> Neurosciences Institut, Hospital Clinic de Barcelona, 08036 Barcelona, Spain; FVALLDE@clinic.ub.es
- <sup>15</sup> Department of Medicine, Universitat de Barcelona, 08036 Barcelona, Spain
- <sup>16</sup> Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain
- <sup>17</sup> Department of Medicine, Universitat Oberta de Catalunya, 08018 Barcelona, Spain
- \* Correspondence: JPagonabarraga@santpau.cat; Tel.: +34-647-618-844; Fax: +34-935-565-748

Received: 11 May 2020; Accepted: 15 May 2020; Published: 22 May 2020



We would like to submit the following erratum to our recently published paper [1] due to the errors in the abstract. We request (1) the removal of the word “motor” from the first line of the abstract, so that the sentence reads: “Safinamide is an approved drug for the treatment of fluctuations in Parkinson’s disease (PD)”, and (2) that the word “OFF” is changed to “ON” in line 6 of the abstract, so that the sentence reads: “Safinamide significantly improves the mean daily ON time without troublesome dyskinesias.”

We apologize for any inconvenience caused to our readers.

**Conflicts of Interest:** The authors declare no conflict of interest.

## Reference

1. Pagonabarraga, J.; Arbelo, J.M.; Grandas, F.; Luquin, M.-R.; Martínez Martín, P.; Rodríguez-Oroz, M.C.; Valldeoriola, F.; Kulisevsky, J. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice. *Brain Sci.* **2020**, *10*, 176. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).